Status:
COMPLETED
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
Brief Summary
The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (In...
Eligibility Criteria
Inclusion
- Patients suffering from BPH symptoms
- Preceding treatment with a phytotherapeutic for at least 4 weeks
- IPSS sum score ≥ 8 points prior to treatment start with ALNA®
- Indication for a switch to treatment with ALNA® for a minimum period of 2 months
Exclusion
- Patients fulfilling one of the general or specific contraindications listed in the ALNA® Summary of Product Characteristic, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency
- Patients receiving ALNA® within the 4 weeks prior to the start of the present observational study
Key Trial Info
Start Date :
September 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
4150 Patients enrolled
Trial Details
Trial ID
NCT02244320
Start Date
September 1 2002
Last Update
September 19 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.